{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected for the analysis of INCB099280 and axitinib concentrations. Per Protocol, PK samples for axitinib were only to be analyzed in case of a concern that axitinib was not as active as expected. Due to the early termination of the study before readout, these samples were not analyzed.","groups":[{"description":"Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.","id":"OG000","title":"INCB099280 400 mg BID Plus Axitinib 5 mg BID"}],"populationDescription":"Pharmacokinetic (PK)-Evaluable Population: all participants who received at least 1 dose of either INB099280 or axitinib and provided at least 1 postbaseline sample for PK analysis. Due to the expected limited number of PK samples from the 5 participants enrolled in this study, analysis of collected PK samples was not conducted, as pre-specified in the Statistical Analysis Plan. Collected samples will not be analyzed in the future.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample","title":"Part 1: INCB099280 and Axitinib Plasma Concentrations","type":"SECONDARY"}